Intriguingly, EZH2 expression is elevated in tumor-infiltrating Tregs, and pharmacological inhibition of EZH2 destabilize FOXP3 expression and slows tumor growth through enhancement of the recruitment and function of CD8+ and CD4+ T cells [95]. The gene discussed is CD8A; the disease is neoplasm.